Skip to main content
Premium Trial:

Request an Annual Quote

Affy Registers Uptick in Q2 Revenue, Narrowed Loss

SAN FRANCISCO, July 25 - Affymetrix yesterday reported a bump up in revenue, decreased losses, and a slight increase in R&D for the second quarter.


Revenue for the period ended June 30 rose to $70.7 million, including $5.6 million from wafers sales from Perlegen Sciences, compared to total revenue of $49.5 million for the second quarter of 2001, the company said.


R&D spending rose to $17.3 million from $16.5 million for the same period a year ago, and net loss decreased to $1.6 million, or $.03 per share, in the second quarter 2002 compared to $9.1 million, or $.16 per share, in the year-ago period.


Affy also reported $134.8 million in cash and cash equivalents at the end on June 2002.


Click here for more information.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.